Todos is also preparing to receive confirmatory data from the second half of an ongoing clinical trial of the Alzheimer’s blood diagnostic LymPro Test through our joint venture, Breakthrough Diagnostics. The importance of this milestone cannot be overstated by virtue of the initial data that we received that demonstrated a very strong correlation with amyloid PET imaging ( p = 0.000002, r = .849).

Coming soon, let's hope it's good.